International Clinical Trial: Exploration of the Efficacy and Safety of metronomic chemotherapy with vinorelbine capsules combined with third-generation EGFR-TKI as First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutations

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115674) titled 'Exploration of the Efficacy and Safety of metronomic chemotherapy with vinorelbine capsules combined with third-generation EGFR-TKI as First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutations' on Dec. 30, 2025.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Beijing hospital

Condition: Lung cancer

Intervention: Metronomic Chemotherapy Combined with Third-Generation EGFR-TKI:1 Third-generation EGFR-TKI: Osimertinib (specification: 80mg/tablet, dosage: 80mg once daily) or Aumolertinib (specification: 55mg/tablet, dosage: 110mg once daily...